Top Markets
Coin of the day
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Clasificación en acciones #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$150.00
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Poniard Pharmaceuticals, Inc. (PARD)

Categoría

Ratio P/S de Poniard Pharmaceuticals, Inc. (PARD)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Poniard Pharmaceuticals, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Poniard Pharmaceuticals, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR